beta-apocarotenoid-14',13'-dioxygenase (ADO)

11/01/1993 - "Ado infusion improved recovery of mechanical function after hypothermic ischemia, and its beneficial effect appears to involve both A1 and A2 receptors. "
11/01/1996 - "They also show that the metabolic and protective effects of Ado depend on the status of the heart before sustained ischemia."
07/01/2001 - "Administration of ADO or SNP on day 1 without IPC produced a similar microvascular protection against prolonged ischemia/reperfusion on day 2 as that induced by IPC alone. "
12/20/2014 - "In the subgroup analysis, among patients with ischemia time below 200 min, the increase in LVEF was slightly higher with ADO (3.59% vs. 0.43%; p for interaction=0.06). "
10/01/2009 - "During ischemia, extracellular levels of both ADO and INO are increased. "

08/01/2013 - "To evaluate safety and efficacy of closure of patent ductus arteriosus (PDA) with Amplatzer duct occluder II Additional Sizes (ADO II AS) and to report early and midterm results of the device in children and very young symptomatic infants. "
06/01/2012 - "The objective of this study was to evaluate the technical feasibility, safety, and efficacy of the new device Amplatzer duct occluder II additional sizes (ADO II AS) for closure of patent ductus arteriosus (PDA). "
05/01/2017 - "The study purpose is to evaluate the safety and efficacy of the ADO II device for closure of patent ductus arteriosus (PDA) in children. "
01/01/2001 - "The aim of the study was to assess the safety and efficacy of the Amplatzer ductal occluder (ADO) in transcatheter occlusion of patent ductus arteriosus (PDA). "
07/15/2004 - "This study compared the efficacy and costs of the most used approaches for percutaneous closure of large patent ductus arteriosus, that is, multiple coils and the Amplatzer duct occluder (ADO) device. "

04/01/2015 - "The purpose of this study was to show that transcatheter closure of perimembranous ventricular septal defect with Amplatzer Ductal Occluder (ADO) is an effective and safe method. "
12/01/2013 - "To show that transcatheter closure of perimembranous ventricular septal defect (PMVSD) with the Amplatzer ductal occluder (ADO, AGA Medical Corp, Plymouth, Minnesota) is a safe and effective treatment option. "
01/01/2021 - "This study was conducted to know the safety and efficacy of transcatheter closure of outlet-type ventricular septal defects (VSDs) with Amplatzer Duct Occluder II (ADO II). "
01/01/2021 - "Objective: The aim of this study was to assess the efficacy and safety of transcatheter retrograde closure of perimembranous ventricular septal defect (pmVSD) via the femoral artery with an Amplatzer Duct Occluder II (ADO II) in children. "
05/01/2019 - "The purpose of this study is to describe the special aspects of perimembranous ventricular septal defects (pmVSD) closure by utilizing Amplatzer Duct Occluder II (ADO II) devices with a rational request for bigger ADO-II sizes, based on our experience in transcatheter device closure of pmVSD. "

12/20/2014 - "Although our study failed to demonstrate that intracoronary administration of ADO prior to PCI limits infarct size, in patients receiving early PCI ADO might enhance myocardial salvage and has a favorable effect on LVEF evolution, which may help to reconcile apparently contradictory results of previous studies. "
05/15/2009 - "It is thus likely that endogenous ADO binding with receptors during early reperfusion is necessary, but nonsufficient to induce protection against infarct size extension."
05/15/2009 - "Neither intermittent ADO nor 3 min continuous ADO can trigger protection against infarct size extension. "
04/01/1997 - "The purpose of the present study was to determine the effects of R-75 on infarct size and to measure myocardial regional Ado concentrations. "
12/20/2014 - "Overall, no significant differences were observed between ADO and placebo regarding infarct size (20.8% vs. 22.5%; p=0.40). "

01/01/2022 - "Adding RVEDVI to three COPD mortality prediction systems improved model fit (pooled chi-square test [BODE: p = 0.05, ADO: p = 0.04, DOSE: p = 0.02]). "
03/29/2022 - "Findings from this study show that the ADO index can predict the medical burden of COPD."
01/01/2021 - "The ADO index was in this study the best predictor and could be a helpful tool in COPD risk assessment."
01/01/2013 - "In this study, the DOSE index was a better predictor of exacerbations of COPD when compared with the BODE and ADO indices."
01/01/2012 - "The updated 15-point ADO index accurately predicts 3-year mortality across the COPD severity spectrum and can be used to inform patients about their prognosis, clinical trial study design or benefit harm assessment of medical interventions."